Research Papers:
The p53 status can influence the role of Sam68 in tumorigenesis
Metrics: PDF 1536 views | HTML 1956 views | ?
Abstract
Naomi Li1,2, Chau Tuan-Anh Ngo1,2, Olga Aleynikova3, Nicole Beauchemin2,4,5, Stéphane Richard1,2
1Terry Fox Molecular Oncology Group and the Bloomfield Center for Research on Aging, Sir Mortimer B Davis Jewish General Hospital, Lady Davis Institute for Medical Research, Montréal, Québec H3T 1E2, Canada
2Department of Medicine and Oncology, McGill University, Montréal, Québec H3A 1A1, Canada
3Department of Pathology, Jewish General Hospital, Montréal, Québec H3T 1E2, Canada
4Department of Biochemistry, McGill University, Montréal, Québec H3G 1Y6, Canada
5Rosalind and Morris Goodman Cancer Centre, Montréal, Québec H3A 1A3, Canada
Correspondence to:
Stéphane Richard, email: [email protected]
Keywords: Sam68, RNA binding protein, p53, tumorigenesis, mouse models
Received: August 08, 2016 Accepted: September 20, 2016 Published: September 28, 2016
ABSTRACT
The expression and activities of RNA binding proteins are frequently dysregulated in human cancer. Their roles, however, appears to be complex, with reports indicating both pro-tumorigenic and tumor suppressive functions. Here we show, using two classical mouse cancer models, that the role of KH-type RNA binding protein, Sam68, in tumor development can be influenced by the status of the p53 tumor suppressor. We demonstrate that in mice expressing wild type p53, Sam68-deficiency resulted in a higher incidence and malignancy of carcinogen-induced tumors, suggesting a tumor suppressive role for Sam68. In marked contrast, Sam68-haploinsufficiency significantly delayed the onset of tumors in mice lacking p53 and prolonged their survival, indicating that Sam68 accelerates the development of p53-deficient tumors. These findings provide considerable insight into a previously unknown relationship between Sam68 and the p53 tumor suppressor in tumorigenesis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12305